DNA Methylation Markers for Breast Cancer Detection in the Developing World.

Publication/Presentation Date

11-1-2019

Abstract

PURPOSE: An unmet need in low-resource countries is an automated breast cancer detection assay to prioritize women who should undergo core breast biopsy and pathologic review. Therefore, we sought to identify and validate a panel of methylated DNA markers to discriminate between cancer and benign breast lesions using cells obtained by fine-needle aspiration (FNA).

RESULTS: In the discovery cohort, 10 of 25 markers were selected that were highly methylated in breast cancer compared with benign tissues by QM-MSP. In the independent test cohort, this panel yielded an AUC of 0.937 (95% CI = 0.900-0.970). In the FNA pilot, we achieved an AUC of 0.960 (95% CI = 0.883-1.0) using the automated cartridge system.

CONCLUSIONS: We developed and piloted a fast and accurate methylation marker-based automated cartridge system to detect breast cancer in FNA samples. This quick ancillary test has the potential to prioritize cancer over benign tissues for expedited pathologic evaluation in poorly resourced countries.

Volume

25

Issue

21

First Page

6357

Last Page

6367

ISSN

1557-3265

Disciplines

Medicine and Health Sciences

PubMedID

31300453

Department(s)

Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology Residents, Fellows and Residents

Document Type

Article

Share

COinS